| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques
|
Titze, Melanie I.
|
|
2016
|
77 |
6 |
p. 1303-1314
|
artikel
|
| 2 |
A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy
|
Li, Fengying
|
|
2016
|
77 |
6 |
p. 1183-1191
|
artikel
|
| 3 |
A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine
|
Jacobs, Bart A.W.
|
|
2016
|
77 |
6 |
p. 1201-1207
|
artikel
|
| 4 |
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors
|
Doi, Toshihiko
|
|
2016
|
77 |
6 |
p. 1253-1262
|
artikel
|
| 5 |
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors
|
Doi, Toshihiko
|
|
|
77 |
6 |
p. 1253-1262
|
artikel
|
| 6 |
A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors
|
Watanabe, K.
|
|
2016
|
77 |
6 |
p. 1157-1164
|
artikel
|
| 7 |
Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study
|
König, Miriam
|
|
2016
|
77 |
6 |
p. 1321
|
artikel
|
| 8 |
Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
|
Tanaka, Yoshihiro
|
|
2016
|
77 |
6 |
p. 1153-1155
|
artikel
|
| 9 |
Evaluation of artemisinins for the treatment of acute myeloid leukemia
|
Drenberg, Christina D.
|
|
2016
|
77 |
6 |
p. 1231-1243
|
artikel
|
| 10 |
Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer
|
Fujii, Hironori
|
|
2016
|
77 |
6 |
p. 1209-1215
|
artikel
|
| 11 |
Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2
|
Ouerdani, Aziz
|
|
2016
|
77 |
6 |
p. 1263-1273
|
artikel
|
| 12 |
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
|
Bryan, Jeffrey C.
|
|
2016
|
77 |
6 |
p. 1125-1142
|
artikel
|
| 13 |
Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
|
Tanaka, Yoshihiro
|
|
2016
|
77 |
6 |
p. 1143-1152
|
artikel
|
| 14 |
Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
|
Nishimura, Goshi
|
|
2016
|
77 |
6 |
p. 1315-1319
|
artikel
|
| 15 |
Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma
|
Li, Jia
|
|
2016
|
77 |
6 |
p. 1193-1200
|
artikel
|
| 16 |
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
|
Bendell, Johanna C.
|
|
2016
|
77 |
6 |
p. 1275-1283
|
artikel
|
| 17 |
Platinum-based drugs: past, present and future
|
Dilruba, Shahana
|
|
2016
|
77 |
6 |
p. 1103-1124
|
artikel
|
| 18 |
Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis
|
Shen, Xiaobing
|
|
2016
|
77 |
6 |
p. 1285-1302
|
artikel
|
| 19 |
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study
|
Sekine, Akimasa
|
|
2016
|
77 |
6 |
p. 1245-1252
|
artikel
|
| 20 |
Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers
|
Jing, Xiaoping
|
|
2016
|
77 |
6 |
p. 1171-1181
|
artikel
|
| 21 |
The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
|
Nishimura, Meiko
|
|
2016
|
77 |
6 |
p. 1165-1170
|
artikel
|
| 22 |
YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo
|
Cai, De
|
|
2016
|
77 |
6 |
p. 1217-1229
|
artikel
|
Tijdschrift beschrijving